ONO-2952 Single-dose PET Study in Healthy Adult Subjects

Completed · Phase 1

Conditions studied: Healthy Adult Subjects

In brief

The primary objective of this study is to evaluate the brain TSPO occupancy of ONO-2952 in healthy adult subjects after a single dose using \[11C\]PBR28 as a specific PET ligand for TSPO. The secondary objective is to evaluate the relationship between TSPO occupancy and the plasma concentration of ONO-2952 and to investigate the safety and tolerability of ONO-2952 in healthy subjects.

Key facts

Study ID

NCT01613703

Run by

Ono Pharma USA Inc

People needed

16

Starts

2012-08-01

Last updated by the study team

2013-06-03

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy non-smoking male or female subjects (18-55 inclusive)
• Body mass index (BMI) of 19-35 kg/m2 (inclusive)
• For females, surgically sterilized, postmenopausal, or who are non- lactating and agree to use a double barrier method of contraception

You may not qualify if…

• History or presence of clinically significant disease

Where it is running

• Pittsburgh Clinical Site — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.